Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- PDAC
- CRC
- NSCLC
- Pancreatic Cancer
- Lung Cancer (NSCLC)
- Advanced Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Revolution Medicines, Inc.
- Last updated on ClinicalTrials.gov
- September 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Yale Cancer Center · New Haven, CT
Maryland · 1
- Johns Hopkins · Baltimore, MD
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Michigan · 1
- START Midwest · Grand Rapids, MI
New York · 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health · New York, NY
Texas · 3
- NEXT - Dallas · Dallas, TX
- NEXT · San Antonio, TX
- START - San Antonio · San Antonio, TX
Virginia · 1
- NEXT - Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.